Published in Drug Week, April 6th, 2001
Brain scans of patients taking glatiramer acetate (GA), sold in the United States as Copaxone, indicate that the drug significantly curtails the number of new brain lesions (injuries) caused by flare-ups of the disease and reduces the overall volume of damaged brain tissue.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.